Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial Evaluating the Effect of Loratadine Associated to Rapamicyn in Patients With Lymphangioleiomyomatosis

NCT05190627 is registered in ClinicalTrials.gov with Institut d'Investigació Biomèdica de Bellvitge as lead sponsor.

NCT NCT05190627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05190627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial Evaluating the Effect of Loratadine Associated to Rapamicyn in Patients With Lymphangioleiomyomatosis
Lead sponsor
Institut d'Investigació Biomèdica de Bellvitge
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2021
Completion date
December 30, 2023
Enrollment
62 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lymphangioleiomyomatosis